News About: Pharm. Industry


Chong Kun Dang signs co-sales agreement of dementia therapy ‘Aricept’ with Eisai Korea

Chong Kun Dang(CEO Young-Joo Kim) signed a co-sales agreement of dementia therapies ‘Aricept’ and ‘Aricept Evess’ with Eisai Korea at the Chong Kun Dang’s headquarters located in Chungjeongno, Seoul on the 28th. Unde...

How Korean listed pharmas with net income in 1Q?

While KOSPI listed pharmaceutical companies had a highly increased net income on average in the 1st quarter of this year year-on-year, KOSDAQ listed pharmaceutical companies met a huge decrease. When it comes to the n...

Shin Poong Pharm to present innovative stroke drug ‘SP-8203’ at BIO USA

Shin Poong Pharm(CEO Jae-Man Yoo) will participate in ‘2018 BIO International Convention,’ the world’s largest biopharmaceutical convention held in Boston between 4 and 7 June, and will announce clinical results about...

How Korean listed pharmas did with operating profits?

In the 1st quarter of this year, KOSPI listed pharmaceutical companies had an increase of over 10% in operating profits year-on-year, but KOSDAQ listed pharmaceutical companies had a negative figure in the same catego...

Il Yang Pharm exports acid reflux therapy ‘Noltec’ to Mongolia for first time

Il Yang Pharm(CEO Dong-Yeon Kim) announced on the 24th ‘Noltec(generic name: ilaprazole),’ a new drug for the treatment of acid reflux, was exported to Mongolia for the first time. This export, the 5th on, of the pro...

‘Big 5’ pharmaceutical companies struggling with overseas sales/exports

The ‘Big 5’ pharmaceutical companies had differing results in overseas sales & exports in this 1st quarter. GC Pharm and Hanmi Pharm had an increase, but the rest failed to do so. When it comes to the ratio of overse...

How listed pharmaceutical companies spent on SG&A expenses in 1st quarter?

In the 1st quarter of this year, KOSDAQ listed pharmaceutical companies had a significantly higher average SG&A(selling, general and administrative) expense increase rate compared to the same quarter of the last year ...

Female officers at listed pharmas show outstanding activities in management, R&D and marketing

The women officer ratio at listed pharmaceutical companies is only 8%, but they are evaluated to distinguish themselves with outstanding activities in various fields, such as sales, marketing and R&D. Yakup Shinmoon(...

Daewoong Pharmaceutical acquires Canadian GMP approval for Nabota factory

The Daewoong Pharmaceutical’s(CEO Seung-Ho Jeon) Nabora factory acquired the cGMP approval from the U.S. FDA on the last 15th, and acquired the GMP approval from the Health Canada on the 18th. Daewoong Pharmaceutical...

Listed pharmas with women officer ratio less than 8%

It is even less than 1 of 10 officers in Korean listed pharmaceutical companies were reportedly women, which criticizes that the Korean pharmaceutical industry is an field with thick glass ceiling. Yakup Shinmoon(www...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.